Sekisui XenoTech Expands Partnership for Japanese Collection of Research Bioresources Cell Bank (JCR

Sekisui XenoTech Expands Partnership for Japanese Collection of Research Bioresources Cell Bank (JCRB) Distribution

Tuesday, January 08, 2019

Exclusive Distributor for JCRB Cell Lines in North America and Europe

 
Kansas City, KS (January 8, 2019) – After 3 years as the official distributor of JCRB cell lines in North America, Sekisui XenoTech has expanded its agreement with the National Institute of Biomedical Innovation to include distribution to Europe. Scientists in both regions will now be able to utilize Sekisui XenoTech in order to easily receive just about any type of cell line that they may need for their research.
 
The JCRB Cell Bank provides over 1,200 cell lines, including:
  • General cells
  • Luciferase-expressing cancer cells
  • Mouse homozygous mutant ES cells
  • Immortalized Mesenchymal stem cells
  • Genetically-modified cells
 
“We are proud to provide JCRB cell line access to European biotechs, pharmas and academia to help facilitate cutting-edge research,” commented Muddasar Farooq, Sekisui XenoTech’s European Territory Manager. He continued, “Our team has worked hard to make this possible. This achievement aligns well with our company’s mission – to lead collaborations with the world’s principal researchers and scientific experts, advancing life-enhancing therapies with unparalleled insight and interpretation through high value products and bespoke services.”
 
Some of the most commonly requested cell lines include:
  • HuH-7 well-differentiated human hepatocellular carcinoma cell line
  • Kuramochi undifferentiated carcinoma, ascites human ovary cell line
  • KMS-11 human hemo-lymphocytic myeloma cell line
  • Ovkate human cell line derived from ovarian tumor
  • QGP-1 carcinoembryonic antigen (CEA)-producing human pancreatic ilet cell carcinoma cell line
  • MBT2 C3H mouse bladder carcinoma cell line
  • Ovsaho human cell line derived from ovarian tumour
  • KHYG-1 human natural killer cell line with a p53 point mutation as a model for p53-associated leukemogenesis and a model for differentiation of NK/T cells
  • HUH-6 Clone 5 JTC38 human hepatoblastoma cell line from an infant
  • JHH-7 HBV integrated human hepato cellular carcinoma cell line
 
Sekisui XenoTech has received very positive customer feedback about JCRB’s cell lines and the company’s distribution process. A senior scientist at a research institute wrote, “We were searching for companies that marketed a particular cell line of interest to us. The cell line was only available at Sekisui XenoTech. Product arrived on time and viability of cells was very good. Customer service was excellent.” A study director for a contract research organization added, “Information provided with the cell line was more than expected and very detailed. Also had the paper describing cell line work performed.”
 
A list of cell lines is available on Sekisui XenoTech’s website. Orders can be placed directly with Sekisui XenoTech or through JCRB’s website. Sekisui XenoTech will handle all of the logistics for shipments to laboratories throughout North America and Europe, including Austria, Belgium, Bulgaria, Canada, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK and USA.
 
About Sekisui XenoTech
Sekisui XenoTech, LLC is a global Contract Research Organization utilized by 98% of top pharma companies and numerous other organizations. For almost 25 years, the company has offered proven drug development expertise, providing an ever-evolving selection of cell and tissue-based products, screening, radiolabeling, API manufacturing, in vitro ADME Tox and pharmacology, in vivo ADME Tox and QWBA, metabolite ID and production, bioanalytical services and consulting. Sekisui XenoTech's product selection includes a wide range of high-quality unique and standard reagents, including subcellular fractions, hepatocytes, media, tissue samples, cell lines, recombinant enzymes, substrates, metabolites and more. The company also regularly prepares and delivers custom-designed products and services in response to client requests. For additional information, please refer to the company's website at www.xenotech.com.
 
About the Japanese Collection of Research Bioresources Cell Bank
JCRB was founded in 1984 by Japan's Ministry of Health, Labor and Welfare. They provide one of the most comprehensive cell banks in the world to users across the globe.